Treatment and prevention of malaria
AssigneeOxford University Innovation Limited
InventorsSimon Draper, Matthew Higgins, Daniel G. W. Alanine
Life of this patent
Estimating the term…
Abstract
There are provided antibodies and combination thereof, and other binding proteins against malarial antigens, as well as said antigens and vectors encoding the antibodies and antigens. The invention also provides the use of such compounds and combinations thereof in the prevention or treatment of malaria. In particular, synergistic combinations of non-neutralising antibodies directed towards an epitope on Reticulocyte-binding protein Homologue 5 (PfRH5) and neutralising antibodies directed towards Plasmodium merozoite antigens are provided.
Claims8
A non-neutralizing antibody, or binding fragment thereof, comprising:
- (a) a heavy chain comprising a CDR1 sequence of SEQ ID NO:
- 11;
- a CDR2 sequence of SEQ ID NO:
- 12 and a CDR3 sequence of SEQ ID NO:
- 13, and a light chain comprising a CDR1 sequence of SEQ ID NO:
- 20;
- a CDR2 sequence of SEQ ID NO:
- 21 and a CDR3 sequence of SEQ ID NO:
- 22;
- or
- (b) a heavy chain comprising a CDR1 sequence of SEQ ID NO:
- 14;
- a CDR2 sequence of SEQ ID NO:
- 15 and a CDR3 sequence of SEQ ID NO:
- 16, and a light chain comprising a CDR1 sequence of SEQ ID NO:
- 23;
- a CDR2 sequence of SEQ ID NO:
- 24 and a CDR3 sequence of SEQ ID NO:
- 25;
- or
- (c) a heavy chain comprising a CDR1 sequence of SEQ ID NO:
- 17;
- a CDR2 sequence of SEQ ID NO:
- 18 and a CDR3 sequence of SEQ ID NO:
- 19, and a light chain comprising a CDR1 sequence of SEQ ID NO:
- 26;
- a CDR2 sequence of SEQ ID NO:
- 21 and a CDR3 sequence of SEQ ID NO:
- 27.
Dependencies are inferred from the claim text.